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Abstract
Background: We had previously established concentrated autologous bone marrow aspirate transplantation
(CABMAT), a one-step, low-invasive, joint-preserving surgical technique for treating osteonecrosis of the femoral
head (ONFH). The present study aimed to evaluate the effects of CABMAT as a hip preserving surgical approach,
preventing femoral head collapse in asymptomatic ONFH.
Methods: In total, 222 patients (341 hips) with ONFH were treated with CABMAT between April 2003 and March 2013.
Based on magnetic resonance imaging, we determined that 119 of these patients had bilateral asymptomatic ONFH
(238 hips), and 38 further patients had unilateral asymptomatic ONFH (38 hips). In this series, we retrospectively
examined 31 hips in 31 patients with unilateral asymptomatic ONFH treated surgically between 2003 and 2012 and
followed up for more than 2 years. Clinical and radiological evaluation were performed immediately before the
procedure and at the final follow-up. The two-year follow-up rate among patients with unilateral ONFH was 82% (31/
38). Therefore, the present study included 31 patients (19 males and 12 females), with a mean age and follow-up
period of 40 and 5.8 years, respectively. Of the 31 asymptomatic hips, 5, 6, 10, and 10 had osteonecrosis of types A, B,
C1, and C2, respectively. The diagnosis, classification, and staging of ONFH were based on the 2001 Japanese
Orthopaedic Association (JOA) classification.
Results: Secondary collapse of the femoral head was observed in 6/10 hips and 5/10 hips with osteonecrosis of types C1
and C2, respectively. Total hip arthroplasty was performed in 9.6% of patients (3/31 hips), at an average of 33 months
after surgery. Clinical symptoms improved after surgery, and the secondary collapse rate at a mean of 5.8 years after
CABMAT was lower than that reported in several previous studies on the natural course of asymptomatic ONFH.
(Continued on next page)
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Conclusions: Early diagnosis of ONFH (i.e., before femoral head collapse) and early intervention with CABMAT could
improve the clinical outcome of corticosteroid and alcohol-induced ONFH.
Keywords: Osteonecrosis of the femoral head, Femoral head collapse, Low-invasive surgery, Bone marrow aspirate,
Autologous transplantation
Background
Idiopathic osteonecrosis of the femoral head (ONFH)
describes atraumatic, aseptic, ischemic necrosis of the
femoral head. In Japan, the incidence of morbidity due
to ONFH is 17 patients per 100,000 persons per year [1].
The peak age at onset has been reported to be in the 40s
and 30s for men and women, respectively, indicating a
potentially significant impact on activities of daily living
(ADL) since this segment of the population is expected
to be at peak performance [1]. Total hip arthroplasty
represents a major treatment option for ONFH in the
elderly. However, joint-preserving treatments such as
core decompression, vascularized bone grafting, femoral
varus osteotomy, and femoral rotational osteotomy are
preferred for young patients.
While conservative therapies such as non-weight bear-
ing and muscle strengthening are available, these are not
effective in most patients with ONFH. Surgical treatment
options for ONFH include core decompression, transtro-
chanteric rotational osteotomy, and other procedures.
Core decompression is less invasive, but the long-term
outcome is unsatisfactory in the majority of patients [2, 3].
Rotational osteotomy is associated with good outcomes in
some but not all patients, and moreover represents a rela-
tively invasive and difficult surgical procedure [4].
Bone marrow is a source of osteoprogenitor cells, which
are key elements in bone formation and fracture healing
[5]. Indeed, failed or delayed fracture healing and ONFH
have been reported to be repaired with autologous bone
marrow transplantation. Hernigou et al. first reported the
results of a prospective study on the benefits of autologous
bone marrow transplantation [6, 7]. Moreover, Gangji et
al. first reported the results of a controlled, double-blind
trial on the efficacy of autologous bone marrow trans-
plantation [6]. In both studies, a cell separator was used to
sort and concentrate only bone marrow nucleated cells for
transplantation, and the authors concluded that concen-
trated bone marrow transplantation improved femoral
head preservation in the early stages of ONFH.
In our institution, we started concentrated autologous
bone marrow aspirate transplantation (CABMAT) in
2003. The bone marrow is aspirated from the iliac crests,
concentrated using a conventional manual blood bag
centrifugation technique to extract buffy coats, and then
injected into hips via drilling [7]. This procedure con-
centrates nucleated cells and platelets from clinical bone
marrow aspirates (BMAs) to obtain osteogenic progeni-
tor cells and growth factors for percutaneous transplant-
ation to the necrotic area. We previously reported on
the efficacy of CABMAT in ONFH [8, 9].
Because ONFH is a rare disease and clinical status
varies significantly with stage, type, and etiology, estab-
lishing a control group is difficult. Hence, performing a
comparative clinical research study represents a challen-
ging task.
Corticosteroid-induced or alcohol-associated ONFH
often affects both femoral heads. In some patients with
bilateral ONFH, one of the hips is symptomatic while
the other may remain asymptomatic. To our knowledge,
there are limited reports regarding the management of
the asymptomatic side.
The purpose of the present study was to evaluate the
therapeutic effects of CABMAT for the treatment of the
asymptomatic hip in patients with bilateral ONFH, rela-
tive to the natural course of asymptomatic ONFH.
Methods
Patients
A total of 222 patients (341 hips) with ONFH were treated
with CABMAT between April 2003 and March 2013.
Based on magnetic resonance imaging, bilateral and
unilateral asymptomatic ONFH was diagnosed in 119 pa-
tients (238 of 341 treated hips; 69.8%) and 38 patients (38
of 341 treated hips, 11.1%), respectively. In this series, we
retrospectively examined 31 of 38 patients with unilateral
asymptomatic ONFH who had been followed-up for two
years or more (two-year follow-up rate, 81.5%).
Among the 31 patients with unilateral asymptomatic
ONFH included in the study (19 males and 12 females),
the mean age was 40.0 years (range, 26–70 years). The
study included 13 right hips and 18 left hips.
The study endpoint was set as the time point of the
most recent follow-up or the time when the patients re-
quired additional surgery (total hip arthroplasty).
Osteonecrosis of the hip was induced by corticosteroids
and alcohol in 28 and 3 hips, respectively. Corticosteroids
were used in 13 of the 28 hips to manage systemic lupus
erythematosus, whereas the remaining 15 patients received
corticosteroids for various reasons (rheumatoid arthritis, 1;
nephrotic syndrome, 1; facial nerve palsy, 1; dermatomyo-
sitis, 1; collagen disease, 1; idiopathic thrombocytopenic
purpura, 2; ulcerative colitis, 1; IgA nephropathy, 2; iritis,
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1; brain infarction, 1; myasthenia gravis, 1; interstitial
pneumonia, 1; and primary biliary liver cirrhosis, 1).
ONFH diagnosis
The diagnosis, classification, and staging of ONFH were
based on the 2001 Japanese Orthopaedic Association
(JOA) classification, which refers to findings on antero-
posterior and lateral plain radiographs or magnetic
resonance imaging scans [10]. Based on these criteria,
ONFH was classified into four types by the location of
necrotic lesions on T1-weighted or X-ray images. Type
A lesions were defined as occupying the medial one
third or less of the weight-bearing portion. Type B le-
sions were defined as occupying the medial two thirds
or less of the weight-bearing portion. Type C1 lesions
were defined as occupying more than the medial two
thirds of the weight-bearing portion without extending
laterally to the acetabular edge. Finally, type C2 lesions
were defined as occupying more than the medial two
thirds of the weight-bearing portion and extending lat-
erally to the acetabular edge. Staging was based on the
anteroposterior and lateral views of the femoral head on
radiographs. Stage 1 was defined in hips with no specific
osteonecrosis findings on radiograph but with specific
findings on magnetic resonance imaging, bone scinti-
gram, or histological examination. Stage 2 was defined
in hips with demarcating sclerosis without collapse of
the femoral head. Stage 3 was defined in hips with
collapse of the femoral head, including crescent sign, but
without joint space narrowing. Stage 3 was further di-
vided into substages 3A and 3B, according to the extent
of femoral head collapse (<3 mm and ≥3 mm, respect-
ively). Finally, stage 4 was defined in hips with osteoarth-
ritic changes. Preoperatively, 5, 6, 10, and 10 of 31 hips
analyzed had osteonecrosis of type A, B, C1, and C2,
respectively. Because all hips were asymptomatic, osteo-
necrosis of stage 3 or 4 was not observed. Specifically, of
the 31 hips included in the study, 11 and 20 hips had
ONFH stage 1 and 2, respectively.
Bone marrow aspiration, concentration, and
transplantation
Bone marrow aspiration, concentration, and transplant-
ation were performed based on the method developed
and previously performed by Sakai et al. and Yoshioka et
al. [7, 8]. Specifically, the bone marrow was aspirated
from both anterior iliac crests by using a bone marrow
harvest needle, and subsequently transferred from the
bone marrow collection kit into a collection bag. The
blood fraction containing the BMA was processed by a
two-step centrifugation method (KUBOTA 9800, Kubota,
Japan) at room temperature. After inverse centrifugation
of the blood bag at 1200 g for 10 min, the erythrocytes
were transferred into the satellite bag until the interface
between the plasma and erythrocyte layer was 15 mm
from the bottom of the bag. Subsequently, using high-
speed centrifugation at 3870 g for 7 min, plasma was
transferred slowly into a satellite bag until approximately
4 cm of plasma were left on top of the buffy coat layer.
Before transplantation, we typically created three multi-
directional holes—central, anteromedial, and posterolater-
al—by percutaneous drilling with a Kirschner wire
(diameter, 2.4 mm) to perforate the interface between the
necrotic lesion and healthy bone. Next, core decompres-
sion was performed via the percutaneous technique with a
4.8-mm diameter trephine (Iso Medical Systems, Tokyo,
Japan), which was inserted into the center of the necrotic
site through the greater trochanter. Its position in the
femoral head and necrotic site was monitored with bi-
plane fluoroscopy, and transplantation was performed.
After the operation, weight bearing was limited for
6 weeks, while non-weight bearing exercise was allowed.
Clinical evaluation
Immediately before the procedure and at each follow-up,
patients were evaluated in terms of the JOA hip score
[11], which is an objective index of hip joint function
quantified using items in three categories including (i)
pain, (ii) hip range of motion, (iii) walking, and (iv) ADL
performance. Clinical outcomes were defined in terms of
the change in JOA hip score between the preoperative
evaluation and the most recent follow-up evaluation.
The JOA hip score is used as part of the preoperative
and postoperative clinical assessment of hip function
[12]. The 100-point scale includes subcategories for pain
(40 points), range of motion (20 points), walking ability
(gait; 20 points), and ADL performance (20 points), with
higher scores indicating better hip function. The rate of
conversion to total hip arthroplasty was also evaluated.
Radiographic evaluation
The anteroposterior and lateral radiographs of the af-
fected hip were obtained at each clinical evaluation.
Radiographic progression of femoral head collapse (from
pre-surgery to the most recent follow-up) was evaluated
in consideration of ONFH classification and staging. The
extent of femoral head collapse was measured by using a
template overlay of circles with increasing diameter (1-
mm increments) [13] (Fig. 1). All radiographs were inde-
pendently evaluated by two observers who were specialists
in orthopedic surgery and authorized by the JOA.
Statistical analysis
The JOA scores before CABMAT and at the most recent
follow-up evaluation after CABMAT were compared
using the paired Student’s t test. Radiological outcomes
of CABMAT-treated hips were compared against those
of untreated hips (natural course of ONFH) and against
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those of hips treated with core decompression, and such
comparisons used χ2 tests, Fisher’s tests, and log rank
test (for survival curves). Data were presented as
mean ± standard deviation. A P-value of <0.05 was
considered to indicate statistical significance. All statis-
tical analyses were performed with IBM SPSS Statistics
version 19.0 (IBM Corporation, Armonk, USA).
Results
Mean follow-up duration
Overall, the mean follow-up period was 5.8 years (range,
2.0–6.9 years). On stratification, according to type of
osteonecrosis, the mean and range of follow-up duration
were 4.1 (2.0–6.5), 3.0 (2.0–3.5), 4.2 (2.0–6.4), and 5.8
(3.7–6.9) years for ONFH of type A, B, C1, and C2,
respectively.
JOA score
The mean and range of the JOA hip score was 88 (72–
100) and 92 (45–100) points before surgery and at the
most recent follow-up evaluation, respectively. One
patient who underwent total hip arthroplasty of the
contralateral side was excluded from this evaluation.
While the mean JOA score improved following CAB-
MAT, the improvement was not statistically significant
(P ≥ 0.05, Student’s t test). The pain score was 40 (40–
40) and 36 (20–40) points before surgery and at the
most recent follow-up, respectively. Although the pain
score decreased significantly after surgery (P < 0.05),
only 6% (2/31) of patients reported pain during walking,
whereas the other patients reported feeling no pain or
slight discomfort in the affected hip.
The JOA walking and ADL scores, respectively, were
15 (10–20) and 19 (10–20) points before surgery, but 16
(10–20) and 18 (6–20) points after surgery, indicating
significant improvement (P < 0.05, Student’s t test).
Finally, the JOA range of motion score was 20 (17–20)
and 19 (9–20) points before and after surgery, respect-
ively, which did not indicate a significant change follow-
ing surgery (Fig. 2).
Rate of conversion to total hip arthroplasty
A total of 9.6% (3/31) of patients underwent total hip
arthroplasty at an average of 33 months after surgery.
Radiographic progression of femoral head collapse after
CABMAT
Among hips with ONFH of types C1 and C2, 6 of 10
hips (60%) and 5 of 10 hips (50%), respectively, exhibited
progression of femoral head collapse. The extent of
collapse is listed in Table 1.
Discussion
CABMAT vs natural course
By comparing the outcomes of CABMAT treatment for
asymptomatic, pre-collapsed ONFH with those associ-
ated with the natural course of ONFH, we could verify
that CABMAT changed the natural course of the disease.
Fig. 1 Measurement of femoral head collapse. Collapse extent is defined as the distance between the overlay circle and the collapsed femoral
head (white arrow). a anteroposterior view. b lateral view (Sugioka view). a’ enlarged view of a b’ enlarged view of b
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Compared to the natural course and the outcomes of
core decompression reported in the past, the outcomes
of ONFH treated with CABMAT were better, as it is dis-
cussed in detail in the following paragraphs. Though
CABMAT was not 100% successful, we found clear evi-
dence that such a procedure can alter the natural course
of the disease in some patients with ONFH.
We further discuss our findings in the context of
current knowledge in the field of ONFH management.
Nevertheless, since it is not possible to accurately match
our study sample to those from previous investigations
in terms of extent and location of ONFH, the compari-
sons should be considered qualitative.
CABMAT vs natural course according to ONFH type
In our study, the overall collapse rate (i.e., for all types
of ONFH) was 42%, noted on a mean follow-up of
5.8 years. The rates of femoral head collapse noted in
hips with ONFH of type A, B, C1, and C2 were 0 of 5
hips (0%), 2 of 6 hips (33%), 6 of 10 hips (60%), and 5 of
10 hips (50%), respectively. Koo and Kim reported a col-
lapse rate of 79% (15/19) in the untreated hip, recorded
on a follow-up of at least 2 years [14]. While the col-
lapse rate noted in our study was significantly better
than that reported by Koo and Kim (log rank test,
P < 0.01) (Fig. 3), it is worth noting that Koo and
Kim used a different definition of the necrotic area.
However, since 21% (4/19) of hips evaluated by Koo
and Kim were symptomatic, a simple comparison
against the outcomes of our study is difficult.
CABMAT vs natural course in ONFH of types C1 or C2
In our study, the collapse rate in hips with ONFH of
types C1 or C2 was 55%, recorded on a mean follow-
up of 5.0 years. Several studies have focused on the
natural course of ONFH of type C, with collapse rates
ranging from 60% to 76% in asymptomatic hips; such
studies had a mean follow-up of 1 year [15], and
8.3 years [16]. The mean collapse rate noted in our
present study (55%) was relatively lower than previ-
ously reported rates [15, 16] (Fig. 4).
CABMAT vs natural course in ONFH of type C2
In our study, the collapse rate in hips with ONFH of
type C2 was 50%, noted on a mean follow-up of 5.0 years.
Min et al. reported a collapse rate of 86% in asymptom-
atic, untreated femoral heads, on a mean follow-up of
8.3 years [16]. The collapse rate reported in our study
for CABMAT-treated hips was significantly better than
that reported by Min et al. in untreated femoral heads
(Fisher’s exact test, P < 0.05).
Fig. 2 Assessment of hip function in terms of the Japanese Orthopaedic Association (JOA) hip score. The JOA hip score is measured on a 100-
point scale comprised of categories for pain (40 points), range of movement (ROM; 20 points), walking ability (gait; 20 points), and activities of
daily living (ADL; 20 points), with higher score indicating better hip function. JOA score of walking and ADL points improved significantly at the
most recent follow-up examination
Table 1 Relationship between hip lesion type and progression of
femoral head collapse. Collapse rate and extent were higher for
osteonecrosis of type C than for osteonecrosis of types A or B
Collapse
distance (mm)
Type Total
A B C1 C2
0 5 4 4 5 18(58%)
0–3 0 2 2 3 7(23%)
3–5 0 0 3 1 4(13%)
5≦ 0 0 1 1 2(6%)
Collapsed hip 0/5 2/6 6/10 5/10 13/31
Collapse rate (%) 0% 33% 60% 50% (42%)
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CABMAT vs core decompression
In our study, the femoral head collapse rate in hips
with ONFH of types A–C2 was 42%, recorded on a
mean follow-up of 5.0 years. Based on several studies
that reported on the outcome of core decompression
for ONFH, the collapse rate ranged from 43% to 82%
[2, 3, 14, 17–19].
The collapse rate noted in our study was significantly
better than the rates reported by Koo and Kim (log rank
test, P < 0.05) (Fig. 5) [14] or by Learmonth et al. (Fisher
exact test, P < 0.05) [17]. Additionally,
Mont et al. [18] and Song et al. [19] reported clinical
success rates of 71% (34/45 hips) and 66% (108/163
hips), respectively, after core decompression. On defin-
ing clinical success as a JOA hip score ≥ 80 points and
no requirement for further surgery, which is the defin-
ition used in these previous studies, the success rate in
the present study is 81% (25/31 hips), which is only mar-
ginally better than the success rates reported by Mont et
al. and Song et al.
CABMAT vs other procedures involving bone marrow
transplantation
Based on several studies that reported on the conversion
rate to total hip arthroplasty after treatment with bone
marrow transplantation, the conversion rate is expected
to range from 6.2% to 15.4% [6, 8, 12] which covers the
value noted in our study (9.6%, 3/31). Specifically,
Hernigou et al. reported a conversion rate of 6.2% (9/
189) for asymptomatic hips (ONFH stage 1 or 2) over a
mean follow-up period of 7 years after transplantation of
bone marrow processed using a cell separator and cen-
trifuge for concentration [6]. Gangji et al. reported a
conversion rate of 15.4% (2/13) for asymptomatic hips
(ONFH stage 1 or 2) over a mean follow-up period of
5 years after transplantation of bone marrow processed
using a cell separator and centrifuge for concentration
[8]. In our study, 9.6% (3/31) of the patients underwent
total hip arthroplasty at an average of 33 months after
surgery, and this conversion rate was not significantly
different from those reported in the studies by Hernigou
et al. and Gangji et al. (P > 0.05, χ2 test).
Mechanism of effectiveness of CABMAT
The exact mechanism of ONFH induced by corticoste-
roids or alcohol remains unclear. Hernigou et al. sug-
gested that ONFH may be a disease of bone cells and
Fig. 3 Survival free from femoral head collapse in ONFH: CABMAT vs natural course. Curves describe outcomes after concentrated autologous
bone marrow aspirate transplantation (CABMAT; present study) and outcomes of the natural course of the disease (taken from reference [14]).
ONFH, osteonecrosis of the femoral head
Fig. 4 Comparison of femoral head collapse rates in ONFH of types
C1 and C2. Data describes outcomes after concentrated autologous
bone marrow aspirate transplantation (CABMAT; present study) and
outcomes of the natural course of the disease (taken from
references [14, 15]). ONFH, osteonecrosis of the femoral head
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mesenchymal stem cells [20], since the numbers and
activity of these cells have been shown to be decreased
in both the hematopoietic and stromal compartments of
the bone marrow in patients with ONFH [6, 7]. In
addition, the number of progenitor cells was significantly
lower in patients undergoing corticosteroid therapy than
in patients who had a different underlying etiology [21].
One of the mechanisms underlying CABMAT effect-
iveness is presumed to be transplantation of bone
marrow graft, which involves introduction of new stem/
progenitor cells to an area with deficient or dead stem/
progenitor cells (necrotic lesion), accelerating bone
formation. On the other hand, it is believed that the
mechanism underlying the therapeutic effect of CAB-
MAT with multiple drillings involves core decompres-
sion [22]. Specifically, core decompression decreases the
intraosseous pressure and opens a channel into the nec-
rotic area, which is speculated to alter the natural course
of necrosis and encourage revascularization and repair.
We drilled three channels to induce migration of nucle-
ated cells and platelets to the necrotic site for bone
regeneration [23].
While CABMAT is a less-invasive surgical option
compared with total hip arthroplasty and osteotomy, it
is more invasive than core decompression, since it
requires aspiration from the iliac crest. Nevertheless, no
infection or tumorigenic transformation was noted in
our patients treated with CABMAT.
Limitations
This study has several limitations. First, because this
was a retrospective study and because ONFH is a rare
disease with large variations in clinical status (stage,
type, etiology), defining a control group was difficult.
The lack of a control group represents a limitation of
this study. Furthermore, we used a small sample size
(31 patients). To validate the efficacy of CABMAT,
prospective studies are warranted, preferably in the
form of multicenter, randomized clinical trials compar-
ing CABMAT outcomes with the natural course of
ONFH and with the outcomes of core decompression.
Additional study limitations include the lack of ad-
equate randomization and matching based on ONFH
stage, ONFH type, sex, and age, which should be con-
sidered in future investigations.
Conclusions
In our study, the collapse rate after CABMAT was lower
than the rate previously reported to be associated with
the natural course of asymptomatic ONFH. These find-
ings suggest that early diagnosis of ONFH (i.e., before
femoral head collapse) and early intervention with CAB-
MAT could improve the clinical outcomes of ONFH. Be-
cause CABMAT is a low-invasive therapy with relatively
good clinical outcomes, it would be the first-choice
treatment for early-stage ONFH.
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